AstraZeneca Building Japan Presence Ahead Of Crestor Loss
This article was originally published in PharmAsia News
Phase III results are expected soon for a Japanese study of Brilinta, and the company hopes to have a fresh start for a new, but slow-growing product.
You may also be interested in...
Growth potential for AstraZeneca's new cardiovascular drug Brilinta and its diabetes franchise were highlighted by the group’s new CEO Pacal Soriot during a third-quarter analysts' call but further details of his strategic thinking must wait at least until the end of January 2013.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.